← Leaderboards
Thomas A Dahl
Single Pixel Biomedical, Inc.
$4,263,364
Attributed
$4,263,364
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2008–12$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$4,263,364 · 4
By mechanism
R44$2,965,974 · 1
R43$1,297,390 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseAntimicrobialSurfaceInfectionAnalogMiconazoleRelapseCellsPathogenIn VitroValidationCandida AlbicansAntifungal AgentsOropharyngeal ThrushOverexpressionAnimalsMicrobial BiofilmsMutantMycosesIn VivoDrug DevelopmentGenome SequencingLeadCandida
Grant awards (8)
Therapy Against Recalcitrant C. albicans Infection$979,417
R44 · FY2012 · AI · contact PI
Therapy Against Recalcitrant C. albicans Infection$999,998
R44 · FY2011 · AI · contact PI
2-adamantanamine Based Therapeutic for Recurrent Oropharyngeal Candidiasis$299,157
R43 · FY2011 · DE · contact PI
Therapy Against Recalcitrant C. albicans Infection$986,559
R44 · FY2010 · AI · contact PI
2-adamantanamine Based Therapeutic for Recurrent Oropharyngeal Candidiasis$298,990
R43 · FY2010 · DE · contact PI
THERAPY AGAINST RECALCITRANT C. albicans INFECTION$299,600
R43 · FY2009 · AI · contact PI
THERAPY AGAINST RECALCITRANT C. albicans INFECTION$299,643
R43 · FY2008 · AI · contact PI
Automated Microscopy for Rare Cancer Cell Detection$100,000
R43 · FY2002 · CA